Lung cancer
Conditions
Interventions
single arm:CalliSpheres drug-eluting beads bronchial arterial chemoembolization
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients with NSCLC confirmed by histology or cytology had obstructive atelectasis (at least one segment of atelectasis) by imaging examination; 2. Patients with at least one measurable lesion (evaluated according to recist1.1) should have TNM stage III or above, and the stage should be based on the International Union against cancer (UICC) staging standard 8th Edition; 3. Patients with no operation indication and failure of conventional treatment such as radiotherapy, chemotherapy, targeting and immunization; 4. Patients aged 18-85 5. Laboratory examination showed that there was no significant abnormality in the main functional organs (1) The standard of blood routine examination should meet the following standards WBC=3.0 × 109/L PLT=100 × 109/L HGB=10.0g/L NEUT#=1.5 × 109/L (2) Biochemical tests should meet the following standards: Liver function: 1 ALT?AST= 1.5 ULN; BIL=1.5 ULN; Renal function: 1 Cr=1.5 ULN BUN:2.86-7.14mmol/L 6. Patients with ECoG = 2; 7. Patients whose expected survival time is more than or equal to 3 months; 8. The subjects volunteered to join the study and signed informed consent, with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with other malignant tumors; 2. Patients with uncontrolled distal metastasis; 3. Patients with a history of major diseases involving the heart, kidney, liver, bone marrow or central nervous system, 4. Patients with uncontrollable diabetes, hypertension or ischemic heart disease; 5. Pregnant or lactating women; 6. Patients whose clinical conditions were not suitable for d-bace (contraindication of arterial puncture) were judged by researchers; 7. Patients with obvious arteriovenous fistula; 8. Those patients whose CTA showed no obvious blood supply artery at the end of tumor circulation before operation; 9. Patients allergic to vinorelbine and iodine contrast media; 10. According to the judgment of the researchers, there are patients with accompanying diseases that seriously endanger the safety of patients or affect the completion of the study; 11. Patients who are currently participating in or have participated in other clinical trials within 4 weeks before surgery; 12. Patients with mental illness or history of psychotropic substance abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Countries
China
Contacts
Public ContactSen Jiang
Shanghai Pulmonary Hospital
Outcome results
None listed